What evidence supports MSC therapy?
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Thousands of studies have been registered on mesenchymal stromal cells, but the quality is uneven: most are small, many are uncontrolled, and few report beyond twelve months. This page explains how to tell those apart, and where each indication actually sits.
The evidence tiers we use
Every condition page on this site shows these five tiers separately in its "Evidence at a glance" panel, plus the number of randomised trials and the main outcomes studied.
| Tier | What it means | What it does not mean |
|---|---|---|
| Mechanism | Laboratory work showing what cells do in culture | Nothing about patients |
| Preclinical | Animal models showing an effect | Most animal findings do not replicate in humans |
| Early human | Phase 1/2, often uncontrolled, primary aim is safety | Improvement may be placebo, natural history or selection |
| Controlled human | Randomised or sham-controlled trials with defined endpoints | Small or single-centre trials still overstate effects |
| Regulatory | A licensed product for that indication | Availability in one country is not approval |
What does the evidence show for mesenchymal stem cell therapy?
The evidence is uneven. Mechanistic and animal data are extensive, early human trials are numerous, and randomised controlled trials exist for a minority of indications such as knee osteoarthritis and graft-versus-host disease. For most conditions marketed online, published human evidence is early-phase, small and often uncontrolled, so benefit is plausible but not established.
Key facts
- Strongest human data
- Knee osteoarthritis, GvHD, some cardiac and autoimmune settings
- Weakest human data
- Most neurodegenerative and anti-ageing indications
- Common study limits
- Small samples, no control arm, short follow-up
- Approved uses
- Very few, and country-specific
What we know
- MSCs act mainly through paracrine signalling and immunomodulation rather than engraftment.
- Randomised evidence supports symptomatic benefit in selected orthopaedic and immune indications.
What remains uncertain
- Whether early-phase signals translate into durable benefit for neurological and systemic conditions.
- Optimal dose, route and repeat interval for nearly every indication.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Where the evidence is strongest and weakest
| Indication | Best available tier | Honest summary |
|---|---|---|
| Knee osteoarthritis | Controlled human | Several randomised trials and meta-analyses report pain and function improvement; trials are small, heterogeneous and short — PubMed |
| Graft-versus-host disease | Controlled human + regulatory precedent | The most mature MSC indication, with approved products in some jurisdictions — PubMed |
| Multiple sclerosis | Controlled human | Randomised trials exist; results on disability endpoints have been mixed — PubMed |
| Autism | Early human | Small trials with mixed and largely unreplicated behavioural outcomes — PubMed |
| Spinal cord injury | Early human | Mostly small uncontrolled series; no established functional benefit — PubMed |
| Parkinson's disease | Early human | Early-phase studies only; cell-replacement work with other cell types is separate — PubMed |
| Anti-ageing / general wellness | Mechanism / preclinical | No controlled human evidence of an effect on ageing. Marketed widely; evidenced poorly. |
How to read a stem cell study
- Was there a control group? Without one, improvement cannot be attributed to the treatment.
- How many patients? Twenty-patient trials generate hypotheses, not conclusions.
- What was the primary endpoint, and was it met? Several high-profile trials report positive secondary endpoints after missing the primary one.
- How long was follow-up? Six months tells you little about a chronic disease.
- Who funded and who registered it? Check the registration record on ClinicalTrials.gov.
- Has it been replicated? A single centre's result is a starting point.
Our position
We are a commercial provider, which is exactly why our evidence statements are written to a fixed vocabulary and reviewed on a schedule rather than written per page by marketing. Where trials have failed, our pages say so. Editorial and evidence policy. Mesenchymal stromal cell (MSC) therapy is not an approved treatment for these indications in the United States, the European Union or the United Kingdom. Nothing on this page is a promise of benefit.
Frequently asked questions
Is there any approved MSC product anywhere?
Yes — a small number, in specific jurisdictions and specific indications (for example graft-versus-host disease). That is not the same as approval for the indications most patients enquire about. Status by country.
Why do clinics quote success rates if the evidence is limited?
Because uncontrolled patient-reported improvement is easy to collect and impossible to interpret. We do not publish success rates for that reason.
What would change your evidence ratings?
A new systematic review, meta-analysis or adequately powered randomised trial, or a regulatory decision. Pages carry a review date and are re-checked at least annually, sooner for high-risk indications.
Read next
Have your records reviewed first
Whether any of this applies to you can only be decided after a physician reviews your medical records. The review is free and there is no obligation to travel.
Request a free medical review